AT-1501 is an ALS treatment invented by ALS TDI. In 2018, became the first drug invented by a non-profit biotech to be tested in humans. In November of 2019, it successfully completed a Phase 1 clinical trial, and a Phase 2 trial is upcoming.

Today, in part one of a new series about the science behind AT-1501, we’re joined by ALS TDI CEO Dr. Steve Perrin, who will walk us through the first steps in the process that lead to the invention of this drug – the research into the mechanisms of how ALS effects the body, the experiments conducted in the lab, and the identification of a target to treat with a new drug.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.